Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluocinonide + tazarotene
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
A topical combination therapy consisting of fluocinonide, a potent glucocorticoid steroid, and tazarotene, a third-generation prescription topical retinoid. This combination is primarily used for the treatment of plaque psoriasis, providing complementary mechanisms of action that enhance efficacy and tolerability compared to monotherapy with either agent.
02
Targets
GR (Glucocorticoid receptor)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on fluocinonide + tazarotene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluocinonide + tazarotene.